Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 641 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo oil Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

NCT01351805
View directory record Official record
Conditions
Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions
Fish Oil, Vitamin D, placebo pill
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure

NCT01534663
View directory record Official record
Conditions
Heart Failure
Interventions
Glutamine and Fish Oil Supplementation, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Immunological Impact of High Olive Oil Consumption

NCT01903304
View directory record Official record
Conditions
Immune Factors
Interventions
Olive Oil
Other
Lead sponsor
Tufts University
Other
Eligibility
65 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure

NCT02271230
View directory record Official record
Conditions
Heart Failure
Interventions
Vitamin D and fish oil, Fish oil (EPA/DHA) alone, Vitamin D alone, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

NCT03750968
View directory record Official record
Conditions
Nutrient Deficiency, Pregnancy Related
Interventions
Carotenoid Group, Control Group
Drug · Dietary Supplement
Lead sponsor
Paul S. Bernstein
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

CHI-907 CBD Extract and Experiences of Test Anxiety

NCT04269252
View directory record Official record
Conditions
Anxiety
Interventions
CHI-907, CHI-804
Other
Lead sponsor
Canopy Growth Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Harrisonburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Not applicable Interventional

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

NCT05116878
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

NCT01027143
View directory record Official record
Conditions
Asthma, Obesity
Interventions
omega-3 polyunsaturated fatty acids, Omega-3 Fatty Acid
Dietary Supplement · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

NCT01361607
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols, Placebo (GA-0034)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Glendale, California • Santa Rosa, California • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic

NCT01861457
View directory record Official record
Conditions
Infectious Disease
Interventions
Nozin® Nasal Sanitizer®, Placebo
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Results available

Use of Aromatherapy to Reduce Symptom Burden

NCT05251337
View directory record Official record
Conditions
Anxiety, Chemotherapy-induced Nausea and Vomiting
Interventions
Essential oils, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

NCT00609180
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo
Behavioral · Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
13 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01200446
View directory record Official record
Conditions
Asthma
Interventions
Docosahexaenoic Acid, Placebo Docosahexaenoic Acid
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211
View directory record Official record
Conditions
Huntington Disease
Interventions
Ethyl-EPA (Miraxion™)
Drug
Lead sponsor
Amarin Neuroscience Ltd
Industry
Eligibility
35 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment

NCT01669200
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Medium Chain Triglyceride Oil, Placebo Oil
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia

NCT01737099
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
DHA-O, Fish oil, Placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 4, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

NCT04181593
View directory record Official record
Conditions
Dry Eye
Interventions
Omega 3 fatty acid, Placebos
Drug
Lead sponsor
OmegaD LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Newport Beach, California • Westminster, California • Largo, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Phase 4 Interventional

Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD

NCT01778647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Stimulants plus Lovaza, Stimulants plus placebo
Dietary Supplement · Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
6 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 4, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

NCT02960217
View directory record Official record
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions
UX007, Placebo
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
6 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Norcross, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 4, 2026, 5:03 PM EDT